340B Drug Pricing Program
A federal district court judge in Indiana Friday agreed with the government’s contention that the 340B statute would permit the Department of Health and Human Services to require that the drug company Eli Lilly offer 340B discounts for drugs distributed by hospitals through community pharmacies,…
Court Order in the Lilly Challenge October 29, 2021
Court Decision on the Lilly Challenge October 29, 2021
Government responds to Hospital 340B Payment Reduction Challenge (Oct. 20, 2021).
The AHA and five other groups late Friday expressed continued support for the 340B drug pricing program and strongly encouraged Congress to protect the program as it considers broader changes to the nation’s health care system as part of a legislative package under reconciliation.
AHA, others express support of the 340B federal drug pricing program and strongly encourage Congress to protect the program as they consider broader changes to our nation’s health care system.
HRSA Refers Drug Companies for Enforcement Regarding 340B Community Pharmacy Actions
In comments on OPPS proposed rule, AHA continues to oppose 340B cuts The AHA continues to oppose the Centers for Medicare & Medicaid Services’ deep payments cuts to certain 340B hospitals, the association told the agency as part of its comments on the calendar year 2022 outpatient prospective…
A new report from the Community Oncology Alliance (COA) once again tries to obfuscate the issue of sky-rocketing drug prices by choosing to blame hospitals rather than the drug companies who set the prices and enjoy double-digit profits at the expense of patients and the providers who serve them.